Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

To date, there is a lack of long-term safety and efficacy data for iron chelation therapy in transfusion-dependent patients with sickle cell disease (SCD). To evaluate the long-term safety and efficacy of deferasirox (a once-daily oral iron chelator), patients with SCD completing a 1-year, Phase II,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Vichinsky, Elliott, Bernaudin, Françoise, Forni, Gian Luca, Gardner, Renee, Hassell, Kathryn, Heeney, Matthew M, Inusa, Baba, Kutlar, Abdullah, Lane, Peter, Mathias, Liesl, Porter, John, Tebbi, Cameron, Wilson, Felicia, Griffel, Louis, Deng, Wei, Giannone, Vanessa, Coates, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2011
Assuntos:
Red Cells and Iron
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170481/
https://ncbi.nlm.nih.gov/pubmed/21592110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2011.08720.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados